Monte Rosa Therapeutics

GLUE

Market cap $637M

Monte Rosa secured a second major Novartis deal, adding $120M upfront and up to $5.7B in milestones to its cash reserves. GLUE advances MRT-8102, a NEK7 molecular glue degrader, into Phase 1 trials targeting inflammatory and cardio-immunology disorders, with key data expected in H1 2026. Strong financial position with $295.5M in cash as of June 2025, supported by multiple big pharma collaborations, funding operations into 2028.

Monte Rosa Therapeutics shares jumped this week after the company expanded its collaboration with Novartis. The Novartis partnership brings significant upfront cash and external QuEEN platform validation. Monte Rosa's molecular glue degraders can target previously undruggable proteins.

GLUE surges 44% after sealing a $5.7B licensing deal with NVS to advance molecular glue degraders for immune diseases.

Monte Rosa Therapeutics (GLUE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Novartis receives an exclusive license to an undisclosed discovery target Novartis also receives options to license two programs from Monte Rosa's  growing preclinical immunology portfolio Monte Rosa to receive an upfront payment of $120 million, plus option maintenance payments, and is eligible for option exercise payments and development, regulatory, and sales milestones, as well as tiered royalties on global net sales Extended cash runway enables Monte Rosa to accelerate preclinical and clinical-stage immunology & inflammation (I&I) pipeline BOSTON, Mass., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced an agreement to collaborate with Novartis to develop novel degraders for immune-mediated diseases.

BOSTON, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will participate in the following investor conferences: Morgan Stanley 23rd Annual Global Healthcare Conference (New York, NY) – September 8, 2025.

Monte Rosa Therapeutics (GLUE) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to a loss of $0.43 per share a year ago.

Monte Rosa Therapeutics (GLUE -1.26%), a biotechnology company developing molecular glue degrader therapies, announced results for the second quarter on August 7, 2025. The standout news was a sharp jump in GAAP revenue, which reached $23.2 million, well above GAAP expectations of $7.4 million.

Phase 1 study of NEK7-directed molecular glue degrader (MGD) MRT-8102 underway, to investigate a potential novel therapeutic approach for treating inflammatory diseases driven by the NLRP3 inflammasome; initial readout anticipated in H1 2026 VAV1-directed MGD MRT-6160 advancing toward anticipated initiation of multiple Phase 2 studies in immune-mediated diseases Phase 1/2 study of GSPT1-directed MGD MRT-2359 advancing in heavily pretreated, castration-resistant prostate cancer patients; additional results on track for H2 2025 Strong cash position expected to fund operations into 2028 through multiple anticipated proof-of-concept clinical readouts BOSTON, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today reported business highlights and financial results for the second quarter ended June 30, 2025. “With the advancement of our third program into clinical development, we continue to efficiently execute across our portfolio of only-in-class and first-in-class molecular glue degraders,” said Markus Warmuth, M.D.

MRT-8102 Phase 1 study includes single and multiple ascending dose cohorts in healthy volunteers and is designed to evaluate safety, pharmacokinetics, NEK7 protein degradation, and other key downstream pharmacodynamic markers; initial results anticipated in H1 2026 Additional Phase 1 cohort designed to evaluate potential early proof of concept in subjects with increased cardiovascular disease (CVD) risk and elevated CRP BOSTON, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that the first subjects have been dosed in a Phase 1 study evaluating MRT-8102, a NEK7-directed MGD being developed for the treatment of inflammatory conditions driven by the NLRP3 inflammasome, IL-1β, and IL-6.